There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.
Therapeutic solutions for CLL, which remains incurable, are a work in progress | Image Credit: NicoElNino - stock.adobe.com
Although important new therapies have displaced chemoimmunotherapy as the first-line treatment for chronic lymphocytic leukemia (CLL), therapeutic solutions for the incurable cancer type remain a work in progress.
However, there are several potential new therapies on the horizon that could soon constitute meaningful options for patients with relapse after treatment, according to a new review published in OncoTargets and Therapy.
The study authors began by reviewing the advances that led to the current treatment paradigm. They said B-cell receptor signaling and intrinsic apoptotic resistance are key to the development of CLL cells, and thus efforts to target those pathways have been widely studied.
The 2 biggest changes in the treatment of CLL in the past decade have been covalent Bruton tyrosine kinase (BTK) inhibitors and the selective B-cell lymphoma 2 (BCL2) inhibitor, venetoclax (Venclexta; Abbvie/Genentech).
“These targeted therapies have dramatically transformed the treatment landscape of CLL and long-term survival can be achieved for many patients even those with high-risk features such as TP53 disruption and complex karyotypes,” the authors noted.
Yet, they said even patients who respond well to these therapies will eventually see their cancers progress.
“In this situation, they have limited treatment options with poor clinical outcomes, which highlights a significant unmet medical need,” they wrote.
They then outlined some of the latest research into novel agents with distinct mechanisms that have been developed for CLL and shown promise.
One area of research has focused on noncovalent BTK inhibitors, including pirtobrutinib (Jaypirca; Eli Lilly) and nemtabrutinib. The former was approved last year by FDA for third-line or later treatment of CLL or small lymphocytic leukemia. These therapies play off the fact that the most common secondary resistance mechanisms to covalent BTK inhibitors are BTK C481 mutations.
“Therefore, novel agents that noncovalently bind to BTK at non-C481 sites have been developed with promising clinical efficacy,” the authors wrote.
Another promising category of emerging therapy is that of BTK degraders, which aim to break down the BTK protein rather than inhibit its function. Several such therapies are currently under investigation, the authors wrote, and although data are preliminary, the early results have been encouraging.
Other approaches under investigation include immunotherapies, such as bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells. The former work by redirecting T cells to tumor cells, the authors explained, “leading to potent tumor cell lysis.” Among the bsAbs under investigation in hematological malignancies like CLL are blinatumomab, a CD3/CD19 bispecific T-cell engager, and epcoritamab, a CD3/CD20 bsAb that redirects and activates T cells to kill CD20-expressing tumor cells.
CAR T cells have led to strong outcomes in some other types of hematological malignancies, leading to the study of those therapies in CLL, the authors said. However, there are still several hurdles to overcome to make the therapy successful in CLL, which the authors said is one reason why combination strategies are being investigated.
They noted one way to speed up the clinical application of emerging treatments is to do more research into potential biomarkers that could help identify the best patients and best treatment sequences for the new therapies.
“Furthermore, effective collaboration among academia, industry, regulatory agents, and patients in multiple regions is increasingly important to efficiently conduct patient-centered clinical trials of novel treatments for CLL,” they concluded.
Reference
Hayama M, Riches JC. Taking the next step in double refractory disease: current and future treatment strategies for chronic lymphocytic leukemia. Onco Targets Ther. 2024;17:181-198. doi:10.2147/OTT.S443924
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More